1. Parisi R., Symmons D.P.M., Griffiths C.E.M., Ashcroft D.M.: Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Investig Dermatol 2013, 133, 377-385.
2.
de Oliveira M.F.S.P., de Oliveira Rocha B., Duarte G.V.: Psoriasis: classical and emerging comorbidities. An Bras Dermatol 2015, 90, 9-20.
3.
Alinaghi F., Calov M., Kristensen L.E., Gladman D.D., Coates L.C., Jullien D., et al.: Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol 2019, 80, 251-265.e19.
4.
Ayala-Fontánez N., Soler D.C., McCormick T.S.: Current knowledge on psoriasis and autoimmune diseases. Psoriasis 2016, 6, 7-32.
5.
Ahmed S.S., Manchanda Y., De A., Das S., Kumar R.: Topical therapy in psoriasis. Indian J Dermatol 2023, 68, 437-445.
6.
Sbidian E., Mezzarobba M., Shourick J., Billionnet C., Coste J., Weill A., et al.: Choice of systemic drugs for the management of moderate-to-severe psoriasis: a cross-country comparison based on National Health Insurance Data. Acta Derm Venereol 2021, 101, adv00473.
7.
Hu X., Li J., Fu M., Zhao X., Wang W.: The JAK/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther 2021, 6, 402.
8.
Szilveszter K.P., Németh T., Mócsai A.: Tyrosine kinases in autoimmune and inflammatory skin diseases. Front Immunol 2019, 10, 1862.
9.
Megna M., Potestio L., Ruggiero A., Cacciapuoti S., Maione F., Tasso M., et al.: JAK inhibitors in psoriatic disease. Clin Cosmet Investig Dermatol 2023, 16, 3129-3145.
10.
Sarabia S., Ranjith B., Koppikar S., Wijeratne D.T.: Efficacy and safety of JAK inhibitors in the treatment of psoriasis and psoriatic arthritis: a systematic review and meta-analysis. BMC Rheumatol 2022, 6, 71.
11.
Vaengebjerg S., Skov L., Egeberg A., Loft N.D.: Prevalence, incidence, and risk of cancer in patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis. JAMA Dermatol 2020, 156, 421-429.
12.
Loft N.D., Vaengebjerg S., Skov L.: Cancer risk in patients with psoriasis: should we be paying more attention? Expert Rev Clin Immunol 2020, 16, 479-492.
13.
Fuxench Z.C.C., Shin D.B., Ogdie Beatty A., Gelfand J.M.: The risk of cancer in patients with psoriasis: a population-based cohort study in the health improvement network. JAMA Dermatol 2016, 152, 282-290.
14.
Esse S., Mason K.J., Green A.C., Warren R.B.: Melanoma risk in patients treated with biologic therapy for common inflammatory diseases. JAMA Dermatol 2020, 156, 787-794.
15.
Liu R., Wan Q., Zhao R., Xiao H., Cen Y., Xu X.: Risk of non-melanoma skin cancer with biological therapy in common inflammatory diseases: a systemic review and meta-analysis. Cancer Cell Int 2021, 21, 614.
16.
Mansilla-Polo M., Morgado-Carrasco D.: Biologics versus JAK inhibitors. part i: cancer risk. A narrative review. Dermatol Ther 2024, 14, 1389-1442.
17.
Krzysztofik M., Brzewski P., Kulbat A., Masajada M., Richter K., Wysocki W.M.: The IL-23/Th17 pathway inhibitors in the treatment of psoriasis and the risk of skin malignancies: a review. Adv Dermatol Allergol 2024, 41, 552-559.
18.
Hu X., Li J., Fu M., Zhao X., Wang W.: The JAK/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther 2021, 6, 402.
19.
Samuel C., Cornman H., Kambala A., Kwatra S.G.: A review on the safety of using JAK inhibitors in dermatology: clinical and laboratory monitoring. Dermatol Ther 2023, 13, 729-749.
20.
Greif C.S., Srivastava D., Nijhawan R.I.: Janus kinase inhibitors and non-melanoma skin cancer. Curr Treat Options Oncol 2021, 22, 11.
21.
Qureshy Z., Johnson D.E., Grandis J.R.: Targeting the JAK/STAT pathway in solid tumors. J Cancer Metastasis Treat 2020, 6, 27.
22.
Thomas S.J., Snowden J.A., Zeidler M.P., Danson S.J.: The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours. Br J Cancer 2015, 113, 365-371.
23.
Delhommeau F., Jeziorowska D., Marzac C., Casadevall N.: Molecular aspects of myeloproliferative neoplasms. Int J Hematol 2010, 91, 165-173.
24.
Verstovsek S., Mesa R.A., Gotlib J., Levy R.S., Gupta V., DiPersio J.F., et al.: A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012, 366, 799-807.
25.
Koskela H.L.M., Eldfors S., Ellonen P., van Adrichem A.J., Kuusanmaki H., Andersson E.I., et al.: Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med 2012, 366, 1905-1913.
26.
Brantley E.C., Nabors L.B., Gillespie G.Y., Choi Y.H., Palmer C.A., Harrison K., et al.: Loss of protein inhibitors of activated STAT-3 expression in glioblastoma multiforme tumors: implications for STAT-3 activation and gene expression. Clin Cancer Res 2008, 14, 4694-4704.
27.
Dulińska-Litewka J., Felkle D., Dykas K., Handziuk Z., Krzysztofik M., Gąsiorkiewicz B.: The role of cyclins in the development and progression of prostate cancer. Biomed Pharmacother 2022, 155, 113742.
28.
Pawlus M.R., Wang L., Hu C.J.: STAT3 and HIF1α cooperatively activate HIF1 target genes in MDA-MB-231 and RCC4 cells. Oncogene 2014, 33, 1670-1679.
29.
Cho K.H., Jeong K.J., Shin S.C., Kang J., Park C.G., Lee H.Y.: STAT3 mediates TGF-β1-induced TWIST1 expression and prostate cancer invasion. Cancer Lett 2013, 336, 167-173.
30.
Stephanou A., Latchman D.S.: STAT-1: a novel regulator of apoptosis. Int J Exp Pathol 2003, 84, 239-244.
31.
Stoiber D., Kovacic B., Schuster C., Schellack C., Karaghiosoff M., Kreibich R., et al.: TYK2 is a key regulator of the surveillance of B lymphoid tumors. J Clin Invest 2004, 114, 1650-1658.
32.
Sexl V., Kovacic B., Piekorz R., Moriggl R., Stoiber D., Hoffmeyer A., et al.: Jak1 deficiency leads to enhanced Abelson-induced B-cell tumor formation. Blood 2003, 101, 4937-4943.
33.
Chen X., Du J., Jiang R., Li L.: MicroRNA-214 inhibits the proliferation and invasion of lung carcinoma cells by targeting JAK1. Am J Transl Res 2018, 10, 1164-1171.
34.
Koti M., Siu A., Clément I., Bidarimath M., Turashvili G., Edwards A., et al.: A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer. Br J Cancer 2015, 112, 1215-1222.
35.
Zhang Y., Molavi O., Su M., Lai R.: The clinical and biological significance of STAT1 in esophageal squamous cell carcinoma. BMC Cancer 2014, 14, 791.
36.
Cui X., Jing X., Yi Q., Long C., Tan B., Li X., et al.: Systematic analysis of gene expression alterations and clinical outcomes of STAT3 in cancer. Oncotarget 2018, 9, 3198-3213.
37.
Liu Y., Huang J., Li W., Chen Y., Liu X., Wang J.: Meta-analysis of STAT3 and phospho-STAT3 expression and survival of patients with breast cancer. Oncotarget 2018, 9, 13060-13067.
38.
Pan Y.M., Wang C.G., Zhu M., Xing R., Cui J.T., Li W.M., et al.: STAT3 signaling drives EZH2 transcriptional activation and mediates poor prognosis in gastric cancer. Mol Cancer 2016, 15, 79.
39.
Liu Y., Liao S., Bennett S., Tang H., Song D., Wood D., et al.: STAT3 and its targeting inhibitors in osteosarcoma. Cell Prolif 2021, 54, e12974.
40.
Yang J., Du J., Wang Y.X., Liu C.R.: Activation of JAK/STAT in ovarian high-grade serous cancers and its prognostic significance. J Peking Univ Health Sci 2023, 55, 270-275.
41.
Messina J.L., Yu H., Riker A.I., Munster P.N., Jove R.L., Daud A.I.: Activated Stat-3 in melanoma. Cancer Control 2008, 15, 196-201.
42.
Hu X., Yuan L., Ma T.: Mechanisms of JAK-STAT signaling pathway mediated by CXCL8 gene silencing on epithelial-mesenchymal transition of human cutaneous melanoma cells. Oncol Lett 2020, 20, 1973-1981.
43.
Niu G., Shain K.H., Huang M., Ravi R., Bedi A., Dalton W.S., et al.: Overexpression of a dominant-negative signal transducer and activator of transcription 3 variant in tumor cells leads to production of soluble factors that induce apoptosis and cell cycle arrest. Cancer Res 2001, 61, 3276-3280.
44.
Xu Q., Briggs J., Park S., Niu G., Kortylewski M., Zhang S., et al.: Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene 2005, 24, 5552-5560.
45.
Becker T.M., Boyd S.C., Mijatov B., Gowrishankar K., Snoyman S., Pupo G.M., et al.: Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factor. Oncogene 2014, 33, 1158-1166.
46.
Liu F., Cao J., Wu J., Sullivan K., Shen J., Ryu B., et al.: Stat3-targeted therapies overcome the acquired resistance to vemurafenib in melanomas. J Investig Dermatol 2013, 133, 2041-2049.
47.
Pansky A., Hildebrand P., Fasler-Kan E., Baselgia L., Ketterer S., Beglinger C., et al.: Defective Jak-STAT signal transduction pathway in melanoma cells resistant to growth inhibition by interferon? Int J Cancer 2000, 85, 720-725.
48.
Jackson D.P., Watling D., Rogers N.C., Banks R.E., Kerr I.M., Selby P.J., et al.: The JAK/STAT pathway is not sufficient to sustain the antiproliferative response in an interferon-resistant human melanoma cell line. Melanoma Res 2003, 13, 219-229.
49.
Garcia-Diaz A., Shin D.S., Moreno B.H., Saco J., Escuin-Ordinas H., Rodriguez G.A., et al.: Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. Cell Rep 2017, 19, 1189-1201.
50.
Ravindran Menon D., Li Y., Yamauchi T., Osborne D.G., Vaddi P.K., Wempe M.F., et al.: EGCG inhibits tumor growth in melanoma by targeting JAK-STAT signaling and its downstream PD-L1/PD-L2-PD1 axis in tumors and enhancing cytotoxic T-cell responses. Pharmaceuticals 2021, 14, 1081.
51.
Xu Y.P., Lv L., Liu Y., Smith M.D., Li W.C., Tan X.M., et al.: Tumor suppressor TET2 promotes cancer immunity and immunotherapy efficacy. J Clin Invest 2019, 129, 4316-4331.
52.
Shin D.S., Zaretsky J.M., Escuin-Ordinas H., Garcia-Diaz A., Hu-Lieskovan S., Kalbasi A., et al.: Primary resistance to PD-1 blockade mediated by JAK1/2 mutations. Cancer Discov 2017, 7, 188-201.
53.
Zaretsky J.M., Garcia-Diaz A., Shin D.S., Escuin-Ordinas H., Hugo W., Hu-Lieskovan S., et al.: Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med 2016, 375, 819-829.
54.
Nguyen T.T., Ramsay L., Ahanfeshar-Adams M., Lajoie M., Schadendorf D., Alain T., et al.: Mutations in the IFNγ-JAK-STAT pathway causing resistance to immune checkpoint inhibitors in melanoma increase sensitivity to oncolytic virus treatment. Clin Cancer Res 2021, 27, 3432-3442.
55.
Gomez G.V.B., Lourenço G.J., Monteiro L.M.O., Rocha R.S., McGrail Fernandez K.A., Recio J.A., et al.: Association of JAK/STAT genetic variants with cutaneous melanoma. Front Oncol 2022, 12, 943483.
56.
Pan F., Wang Q., Li S., Huang R., Wang X., Liao X., et al.: Prognostic value of key genes of the JAK‑STAT signaling pathway in patients with cutaneous melanoma. Oncol Lett 2020, 19, 1928-1946.
57.
Burgo M.A., Roudiani N., Chen J., Santana A.L., Doudican N., Proby C., et al.: Ruxolitinib inhibits cyclosporine-induced proliferation of cutaneous squamous cell carcinoma. JCI Insight 2018, 3, e120750.
58.
Chen L., Zhou B., Tang M., Yao Y., Zhao Y., Hu Y., et al.: Aberrant expression of B7-H4 and B7-H5 contributes to the development of cutaneous squamous cell carcinoma. Arch Dermatol Res 2024, 316, 382.
59.
Uribe P., Gonzalez S.: Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy. Pathol Res Pract 2011, 207, 337-342.
60.
Berekmeri A., Mahmood F., Wittmann M., Helliwell P.: Tofacitinib for the treatment of psoriasis and psoriatic arthritis. Expert Rev Clin Immunol 2018, 14, 719-730.
61.
Krzysztofik M., Brzewski P., Cuber P., Kacprzyk A., Kulbat A., Richter K., et al.: Risk of melanoma and non-melanoma skin cancer in patients with psoriasis and psoriatic arthritis treated with targeted therapies: a systematic review and meta-analysis. Pharmaceuticals 2023, 17, 14.
62.
Olivera P.A., Lasa J.S., Bonovas S., Danese S., Peyrin-Biroulet L.: Safety of Janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: a systematic review and meta-analysis. Gastroenterology 2020, 158, 1554-1573.e12.
63.
Russell M.D., Stovin C., Alveyn E., Adeyemi O., Chan C.K.D., Patel V., et al.: JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications. Ann Rheum Dis 2023, 82, 1059-1067.
64.
Bezzio C., Vernero M., Ribaldone D.G., Alimenti E., Manes G., Saibeni S.: Cancer risk in patients treated with the JAK inhibitor tofacitinib: systematic review and meta-analysis. Cancers 2023, 15, 2197.
65.
Huss V., Bower H., Hellgren K., Frisell T., Askling J.: Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study. Ann Rheum Dis 2023, 82, 911-919.
66.
Jalles C., Lepelley M., Mouret S., Charles J., Leccia M.T., Trabelsi S.: Skin cancers under Janus kinase inhibitors: a World Health Organization drug safety database analysis. Therapies 2022, 77, 649-656.
67.
Burmester G.R., Curtis J.R., Yun H., Fitzgerald O., Winthrop K.L., Azevedo V.F., et al.: An integrated analysis of the safety of tofacitinib in psoriatic arthritis across phase III and long-term extension studies with comparison to real-world observational data. Drug Saf 2020, 43, 379-392.
68.
Burmester G.R., Winthrop K., Blanco R., Nash P., Goupille P., Azevedo V.F., et al.: Safety profile of upadacitinib up to 3 years in psoriatic arthritis: an integrated analysis of two pivotal phase 3 trials. Rheumatol Ther 2022, 9, 521-539.
69.
Lebwohl M., Warren R.B., Sofen H., Imafuku S., Paul C., Szepietowski J.C., et al.: Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials. Br J Dermatol 2024, 190, 668-679.
